Dr. Wen Luo is the founder and CEO of a leading precision medicine company, Denovo Biopharma. Dr. Luo has 20 years of experience in biomedical research and industry including more than 10 years of experience in applying genomic technology in drug discovery and development. Prior to joining Denovo Biopharma, Dr. Luo managed the genomic group and provided bioinformatic supports to a broad range of research projects across a number of therapeutic areas including oncology, hematology, inflammation and metabolic diseases at Ligand Pharmaceuticals. He was also responsible for developing clinical biomarkers for drugs in various stages of clinical trials. Before joining Ligand, he was senior bioinformatician at Incyte Genomic, where he managed one of the largest proteomic databases at the time, LifePro. He was also involved in discovering novel human genes and splice variants, and he was the co-inventor of patents covering 100s of novel genes derived from these findings. Prior to Incyte Genomics, he was a research scientist at Sugen (acquired by Pharmacia and then by Pfizer) working on drug target identification and validation for a number of novel kinases discovered at Sugen. Dr. Luo was a Howard Hughes Medical Institute post-doc fellow at UCSF, and received his Ph.D. in molecular biology and biochemistry from Indiana University School of Medicine. Dr. Luo received Pre-Med training at Peking University and medical training at Peking Union Medical College.